Articles

HIV, drugs and the kidney

Nicola Wearne MBChB, FCP, MMed, Bianca Davidson MBChB, FCP, MMed, Marc Blockman MBChB, BPharm, PG Dip Int Res Ethics, MMed, Annoesjka Swart BScPharm, Erika SW Jones MBBCh, FCP, PhD

Article Type

Review

Published

This review discusses antiretroviral therapy and its nephrotoxic effects, including drug–drug interactions. It aims to guide the clinician on dose adjustment in the setting of renal impairment and dialysis, for the commonly used drugs in patients with HIV.

Read more

Management of psoriasis in pregnancy – a review of the evidence to date

Clara Ferreira MD, Alexandra Azevedo MD, Miguel Nogueira MD, Tiago Torres MD, PhD

Article Type

Review

Published

This article reviews the impact of psoriasis during pregnancy, how the disease can be managed pharmacologically during this period according to the available armamentarium, and the possible effects of the therapeutic options for the mother and the foetus.

Read more

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection

Hanh Thi Pham PhD, Meng A Xiao BSc, Miguel AV Principe BSc, Alexander Wong MD, Thibault Mesplède PhD

Article Type

Review

Published

This review summarizes chemical, pharmacological, and clinical information about doravirine with an emphasis on drug resistance. The efficacy results from an early phase clinical trial evaluating doravirine in combination with islatravir are also provided.

Read more

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure

Edgardo Kaplinsky MD

Article Type

Review

Published

This review describes the results of the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial and the recently published Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction (DEFINE-HF) trial. In addition, the thought-to-be mechanisms of action of SGLT2 inhibitors beyond their known glucose-lowering effects.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.